• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Tesla Posts Weak Earnings, Joins Visa, Deutsche Bank And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

    7/24/24 8:17:24 AM ET
    $BZ
    $DB
    $GERN
    $GOOGL
    Computer Software: Programming Data Processing
    Technology
    Major Banks
    Finance
    Get the next $BZ alert in real time by email

    U.S. stock futures were lower this morning, with the Nasdaq futures dipping around 200 points on Wednesday.

    Shares of Tesla, Inc. (NASDAQ:TSLA) fell sharply in today's pre-market trading following second-quarter results.

    Tesla reported second-quarter revenue of $25.5 billion, up 2% year-over-year. The revenue total beat a Street consensus estimate of $24.73 billion, according to data from Benzinga Pro. The company reported earnings per share of 52 cents in the second quarter, down 43% year-over-year. The earnings per share missed a Street consensus estimate of 62 cents per share.

    The company reported second-quarter deliveries of 443,956 vehicles and production of 410,831 vehicles, down 5% and 14% year-over-year, respectively.

    Tesla shares dipped 7.2% to $228.56 in the pre-market trading session.

    Here are some big stocks recording losses in today's pre-market trading session.

    • Wheels Up Experience Inc. (NYSE:UP) shares dipped 9.8% to $3.00 in pre-market trading. Wheels Up Experience will release its second quarter financial results on Thursday, Aug. 8.
    • SFL Corporation Ltd. (NYSE:SFL) shares fell 9.3% to $12.65 in pre-market trading after the company announced an offering of 8 million common shares.
    • Serve Robotics Inc. (NASDAQ:SERV) shares declined 7.5% to $8.70 in pre-market trading after gaining 7% on Tuesday.
    • Deutsche Bank Aktiengesellschaft (NYSE:DB) shares fell 7.5% to $15.77 in pre-market trading following second-quarter earnings.
    • Geron Corporation (NASDAQ:GERN) shares declined 6.9% to $4.30 in pre-market trading after the company announced the departure of CCO Anil Kapur.
    • Kanzhun Limited (NASDAQ:BZ) shares fell 5.8% to $15.00 in pre-market trading.
    • Alphabet Inc. (NASDAQ:GOOGL) shares declined 3.2% to $176.00 in pre-market trading. Alphabet reported upbeat earnings and sales results for its second quarter on Tuesday. The company also announced a cash dividend of 20 cents per share to be paid on Sept.16 to shareholders of record as of Sept. 9.
    • Visa Inc. (NYSE:V) shares fell 3% to $256.94 in pre-market trading following third-quarter results.

    Now Read This:

    • US Stocks End Lower As Investor Optimism Decreases Ahead Of Big Tech Earnings
    Get the next $BZ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BZ
    $DB
    $GERN
    $GOOGL

    CompanyDatePrice TargetRatingAnalyst
    Alphabet Inc.
    $GOOGL
    2/23/2026$387.00Equal Weight → Overweight
    Wells Fargo
    Tesla Inc.
    $TSLA
    2/12/2026$550.00Buy
    Tigress Financial
    Visa Inc.
    $V
    2/3/2026$370.00Neutral → Outperform
    Daiwa Securities
    Tesla Inc.
    $TSLA
    1/30/2026$150.00 → $145.00Underweight
    Analyst
    Visa Inc.
    $V
    1/28/2026$385.00Neutral → Buy
    Rothschild & Co Redburn
    Visa Inc.
    $V
    1/27/2026$400.00Overweight
    Cantor Fitzgerald
    Alphabet Inc.
    $GOOGL
    1/26/2026$330.00 → $360.00Overweight
    KeyBanc Capital Markets
    Alphabet Inc.
    $GOOGL
    1/23/2026$333.00 → $346.00Buy
    Stifel
    More analyst ratings

    $BZ
    $DB
    $GERN
    $GOOGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alphabet A upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Alphabet A from Equal Weight to Overweight and set a new price target of $387.00

    2/23/26 8:28:41 AM ET
    $GOOGL
    Computer Software: Programming Data Processing
    Technology

    Tigress Financial resumed coverage on Tesla with a new price target

    Tigress Financial resumed coverage of Tesla with a rating of Buy and set a new price target of $550.00

    2/12/26 10:13:29 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    Visa upgraded by Daiwa Securities with a new price target

    Daiwa Securities upgraded Visa from Neutral to Outperform and set a new price target of $370.00

    2/3/26 7:57:45 AM ET
    $V
    Real Estate

    $BZ
    $DB
    $GERN
    $GOOGL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 7, 2024 - FDA Roundup: June 7, 2024

    For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

    6/7/24 3:46:22 PM ET
    $GERN
    $SRAX
    $SNAP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Advertising
    Consumer Discretionary

    FDA Approval for RYTELO issued to GERON CORP

    Submission status for GERON CORP's drug RYTELO (ORIG-1) with active ingredient IMETELSTAT has changed to 'Approval' on 06/06/2024. Application Category: NDA, Application Number: 217779, Application Classification: Type 1 - New Molecular Entity

    6/7/24 12:36:59 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BZ
    $DB
    $GERN
    $GOOGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Musk Elon bought $999,959,042 worth of shares (2,568,732 units at $389.28) (SEC Form 4)

    4 - Tesla, Inc. (0001318605) (Issuer)

    9/15/25 6:01:19 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    Director Lawlis V Bryan bought $15,667 worth of shares (13,300 units at $1.18) (SEC Form 4)

    4 - GERON CORP (0000886744) (Issuer)

    5/13/25 4:20:43 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Gebbia Joseph bought $1,025,232 worth of shares (4,000 units at $256.31) (SEC Form 4)

    4 - Tesla, Inc. (0001318605) (Issuer)

    4/28/25 6:45:17 PM ET
    $TSLA
    Auto Manufacturing
    Industrials

    $BZ
    $DB
    $GERN
    $GOOGL
    SEC Filings

    View All

    SEC Form 144 filed by Tesla Inc.

    144 - Tesla, Inc. (0001318605) (Subject)

    2/25/26 4:27:12 PM ET
    $TSLA
    Auto Manufacturing
    Industrials

    Geron Corporation filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - GERON CORP (0000886744) (Filer)

    2/25/26 7:15:13 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serve Robotics Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - Serve Robotics Inc. /DE/ (0001832483) (Filer)

    2/20/26 4:05:50 PM ET
    $SERV
    Industrial Specialties
    Consumer Discretionary

    $BZ
    $DB
    $GERN
    $GOOGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief People Officer Kedzior Brian Joseph covered exercise/tax liability with 2,007 shares, decreasing direct ownership by 0.25% to 790,242 units (SEC Form 4)

    4 - Wheels Up Experience Inc. (0001819516) (Issuer)

    2/25/26 8:00:48 PM ET
    $UP
    Transportation Services
    Consumer Discretionary

    Chief Sales Officer Briffa Mark covered exercise/tax liability with 4,958 shares, decreasing direct ownership by 0.58% to 856,585 units (SEC Form 4)

    4 - Wheels Up Experience Inc. (0001819516) (Issuer)

    2/25/26 8:00:15 PM ET
    $UP
    Transportation Services
    Consumer Discretionary

    Director Sergey Brin gifted 437,500 units of Class C Capital Stock and gifted 437,500 shares, increasing direct ownership by 75,659% to 359,833,112 units (SEC Form 4)

    4 - Alphabet Inc. (0001652044) (Issuer)

    2/25/26 7:17:50 PM ET
    $GOOGL
    Computer Software: Programming Data Processing
    Technology

    $BZ
    $DB
    $GERN
    $GOOGL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Serve Robotics to Report Fourth Quarter 2025 Financial Results, Host Conference Call and Webcast on March 11

    SAN FRANCISCO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Serve Robotics Inc. ("Serve") (NASDAQ:SERV), a leading autonomous robotics company, today announced that it will report its 2025 fourth quarter financial results before the opening of regular trading on Wednesday, March 11, 2026. The company will host a conference call and webcast to review the results on the same day. Conference Call and Webcast InformationCompany management will host a conference call at 8 a.m. PT / 11 a.m. ET. A live audio webcast will be available at investors.serverobotics.com and a replay will be available at the same location. Analysts and investors who wish to submit questions to management may send an email to inv

    2/25/26 7:30:00 AM ET
    $SERV
    Industrial Specialties
    Consumer Discretionary

    Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

    Achieved $48 million and $184 million in RYTELO® (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating expenses of $255 million for full year 2025, within the previous guidance range Reiterated 2026 RYTELO net product revenue and total operating expenses expected in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively Ended 2025 with cash, cash equivalents, restricted cash and marketable securities of roughly $401 million Company to host conference call and webcast today, February 25, at 8:00 a.m. ET FOSTER CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial

    2/25/26 7:00:00 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Geron Plans to Present at Upcoming Investor Conferences

    FOSTER CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to present at the following investor conferences: TD Cowen 46th Annual Healthcare ConferenceFireside Chat on Monday, March 2 at 1:10 p.m. ET in Boston, MABarclays 28th Annual Global Healthcare ConferenceFireside Chat on Tuesday, March 10 at 10:30 a.m. ET in Miami, FLLeerink Partners Global Healthcare ConferenceIn-Person Meetings on Wednesday, March 11 in Miami, FL A live and archived audio webcast of each fireside chat will be

    2/23/26 8:00:00 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BZ
    $DB
    $GERN
    $GOOGL
    Leadership Updates

    Live Leadership Updates

    View All

    Visa Foundation Board Appoints Najada Kumbuli as President of Visa Foundation

    Visa (NYSE:V), a global leader in digital payments, today announced that Najada Kumbuli has been appointed President of Visa Foundation, effective immediately. With guidance from the Board, Kumbuli will be responsible for managing Visa Foundation's impact investing and grantmaking, and will also serve as Visa Inc.'s head of global philanthropy. Kumbuli has more than 15 years of experience in investment strategy, impact evaluation, and leadership of global philanthropic programs. Prior to Visa Foundation, she served as the Investment Director at Calvert Impact Capital, a global impact investment firm. Kumbuli succeeds Graham Macmillan, who served as Visa Foundation's president since 2019.

    12/11/25 10:30:00 AM ET
    $V
    Real Estate

    Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

    Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

    12/4/25 12:20:00 PM ET
    $GERN
    $GTBP
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Scientists Pointing to Hidden Power Source That Could Reshape Future of AI

    This article has been disseminated on behalf of MAX Power Mining Corp. and may include a paid advertisement. AUSTIN, Texas, Dec. 03, 2025 (GLOBE NEWSWIRE) -- MiningNewsWire: Global electricity demand is reaching a pivotal turning point. The International Energy Agency (IEA) now projects that global data-center electricity use will almost double by 2030, with AI-focused facilities increasing their consumption more than four times over the same span — a trajectory pushing power grids in the United States, China, Europe, Southeast Asia and other regions to their limits. The bottleneck is no longer data throughput or semiconductor performance; the critical constraint has become electricity it

    12/3/25 8:30:00 AM ET
    $AMZN
    $AVGO
    $META
    Catalog/Specialty Distribution
    Consumer Discretionary
    Semiconductors
    Technology

    $BZ
    $DB
    $GERN
    $GOOGL
    Financials

    Live finance-specific insights

    View All

    Serve Robotics to Report Fourth Quarter 2025 Financial Results, Host Conference Call and Webcast on March 11

    SAN FRANCISCO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Serve Robotics Inc. ("Serve") (NASDAQ:SERV), a leading autonomous robotics company, today announced that it will report its 2025 fourth quarter financial results before the opening of regular trading on Wednesday, March 11, 2026. The company will host a conference call and webcast to review the results on the same day. Conference Call and Webcast InformationCompany management will host a conference call at 8 a.m. PT / 11 a.m. ET. A live audio webcast will be available at investors.serverobotics.com and a replay will be available at the same location. Analysts and investors who wish to submit questions to management may send an email to inv

    2/25/26 7:30:00 AM ET
    $SERV
    Industrial Specialties
    Consumer Discretionary

    Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

    Achieved $48 million and $184 million in RYTELO® (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating expenses of $255 million for full year 2025, within the previous guidance range Reiterated 2026 RYTELO net product revenue and total operating expenses expected in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively Ended 2025 with cash, cash equivalents, restricted cash and marketable securities of roughly $401 million Company to host conference call and webcast today, February 25, at 8:00 a.m. ET FOSTER CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial

    2/25/26 7:00:00 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

    FOSTER CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its fourth quarter and full year 2025 financial results and business highlights before the market opens on Wednesday, February 25, 2026 via press release, which will be available on the Investors and Media section of the Company's website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time. A live and archived audio webcast of the conference call will be available from the Investors and Media section of the Company's website at www.geron.c

    2/11/26 7:27:26 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BZ
    $DB
    $GERN
    $GOOGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Geron Corporation

    SC 13G/A - GERON CORP (0000886744) (Subject)

    11/14/24 5:46:12 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Wheels Up Experience Inc.

    SC 13D/A - Wheels Up Experience Inc. (0001819516) (Subject)

    11/14/24 4:30:05 PM ET
    $UP
    Transportation Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Geron Corporation

    SC 13G/A - GERON CORP (0000886744) (Subject)

    11/14/24 9:31:41 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care